My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking ...

PART I. FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) The company reported increased revenue and a higher net loss due to rising R&D expenses, leading to increased cash used in operations [Condensed Balance Sheets](index=6&type=section&id=Condensed%20Balance%20Sheets) Condensed Balance Sheet Highlights | Account | May 31, 2025 (in thousands) | November 30, 2024 (in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $84,260 | $109,997 | | Marketable securities, current | $401,521 | $499,586 | | Total current assets | $515,330 | $619,387 | | Total assets | $591,555 | $669,343 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $75,614 | $95,854 | | Total liabilities | $143,952 | $142,350 | | Total stockholders' equity | $447,603 | $526,993 | | Accumulated deficit | $(838,584) | $(738,769) | [Condensed Statements of Operations](index=7&type=section&id=Condensed%20Statements%20of%20Operations) Condensed Statements of Operations Highlights | Metric | Three Months Ended May 31, 2025 (in thousands) | Three Months Ended May 31, 2024 (in thousands) | Six Months Ended May 31, 2025 (in thousands) | Six Months Ended May 31, 2024 (in thousands) | | :--- | :--- | :--- | :--- | :--- | | Collaboration revenue | $14,056 | $12,092 | $32,509 | $28,677 | | License revenue | $30,000 | $— | $30,000 | $— | | **Total revenue** | **$44,056** | **$12,092** | **$62,509** | **$28,677** | | Research and development | $78,096 | $48,922 | $147,759 | $98,927 | | General and administrative | $14,282 | $11,710 | $25,936 | $23,509 | | **Total operating expenses** | **$92,378** | **$60,632** | **$173,695** | **$122,436** | | **Net loss** | **$(43,464)** | **$(44,546)** | **$(99,815)** | **$(86,064)** | | Net loss per share | $(0.52) | $(0.71) | $(1.19) | $(1.47) | [Condensed Statements of Cash Flows](index=11&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Condensed Statements of Cash Flows Highlights | Activity | Six Months Ended May 31, 2025 (in thousands) | Six Months Ended May 31, 2024 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | $(124,248) | $(81,656) | | Net cash provided by (used in) investing activities | $97,032 | $(95,557) | | Net cash provided by financing activities | $1,479 | $239,376 | | **Net (decrease) increase in cash, cash equivalents and restricted cash** | **$(25,737)** | **$62,163** | [Notes to Condensed Financial Statements](index=13&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) - The company is a clinical-stage biopharmaceutical firm leveraging its DEL-AI platform to develop small molecule and antibody therapies for cancer and inflammatory diseases, with a pipeline including wholly-owned candidates and partnered programs with Gilead, Sanofi, and Pfizer[32](index=32&type=chunk) - Management believes its cash, cash equivalents, and marketable securities totaling **$485.8 million** as of May 31, 2025, are sufficient to fund operating activities for at least 12 months[41](index=41&type=chunk) - Sanofi's exercise of exclusive license rights for two development candidates in March and May 2025 generated **$30.0 million** in license revenue for Nurix during the second quarter of fiscal year 2025[76](index=76&type=chunk)[83](index=83&type=chunk) - A new lease agreement in Brisbane, CA for approximately **159,959 sq. ft.** of R&D and office space in February 2025 resulted in a **$26.7 million** right-of-use asset and lease liability[108](index=108&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=30&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) The company's net loss increased due to higher R&D expenses, despite revenue growth, while maintaining sufficient liquidity for the next 12 months [Overview](index=30&type=section&id=Overview) - Nurix is a clinical-stage biopharmaceutical company focused on targeted protein degradation utilizing its DEL-AI discovery engine[131](index=131&type=chunk) - The wholly-owned clinical pipeline features BTK degraders **bexobrutideg (NX-5948)** and **zelebrudomide (NX-2127)**, alongside CBL-B inhibitor **NX-1607**[131](index=131&type=chunk)[132](index=132&type=chunk)[135](index=135&type=chunk) - Major collaborations with Gilead, Sanofi, and Pfizer have provided **$482.0 million** in non-dilutive financing to date, with potential for up to **$6.1 billion** in future fees and milestones[138](index=138&type=chunk) - **Bexobrutideg (NX-5948)** received Fast Track designation from the FDA for CLL/SLL and WM, and Orphan Drug Designation from both the FDA and EMA for WM/lymphoplasmacytic lymphoma, with a Phase 2 trial expected to commence in 2025[133](index=133&type=chunk) [Results of Operations](index=38&type=section&id=Results%20of%20Operations) Comparison of Operations | Item | Six Months Ended May 31, 2025 (in thousands) | Six Months Ended May 31, 2024 (in thousands) | Change (in thousands) | | :--- | :--- | :--- | :--- | | Total revenue | $62,509 | $28,677 | $33,832 | | Research and development | $147,759 | $98,927 | $48,832 | | General and administrative | $25,936 | $23,509 | $2,427 | | **Net loss** | **$(99,815)** | **$(86,064)** | **$(13,751)** | - **$30.0 million** in license revenue for the three and six months ended May 31, 2025, was recognized from the Sanofi License Extensions[184](index=184&type=chunk) - R&D expenses increased by **$48.8 million** for the six months ended May 31, 2025, primarily due to higher clinical, manufacturing, and consulting costs to accelerate bexobrutideg (NX-5948) enrollment and prepare for pivotal trials[185](index=185&type=chunk) [Liquidity and Capital Resources](index=40&type=section&id=Liquidity%20and%20Capital%20Resources) - As of May 31, 2025, the company held **$485.8 million** in cash, cash equivalents, and marketable securities[196](index=196&type=chunk) - Management anticipates existing cash will be sufficient to fund operations for at least the next 12 months[197](index=197&type=chunk) - Net cash used in operating activities increased to **$124.2 million** for the six months ended May 31, 2025, from **$81.7 million** in the prior year, driven by a higher net loss and working capital changes, including a **$19.0 million** increase in accounts receivable from the Sanofi license extension[203](index=203&type=chunk)[204](index=204&type=chunk) - Net cash provided by financing activities was **$1.5 million** in the first six months of fiscal 2025, significantly lower than **$239.4 million** in the prior year period, which included proceeds from a public offering and ATM financing[207](index=207&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes in market risks since its last Annual Report on Form 10-K - No material changes in market risks have occurred since the Annual Report on Form 10-K filed on January 28, 2025[208](index=208&type=chunk) [Controls and Procedures](index=44&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective, with no material changes in internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of May 31, 2025[210](index=210&type=chunk) - No changes materially affected internal control over financial reporting during the quarter[211](index=211&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=45&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings - As of the report date, the company is not a party to any material legal proceedings[214](index=214&type=chunk) [Risk Factors](index=45&type=section&id=Item%201A.%20Risk%20Factors) The company faces substantial risks including financial losses, early-stage pipeline uncertainty, reliance on third parties, commercialization challenges, and regulatory hurdles [Risks Related to Our Financial Position and Need for Additional Capital](index=45&type=section&id=Risks%20Related%20to%20Our%20Financial%20Position%20and%20Need%20for%20Additional%20Capital) - The company has a history of significant losses, with a net loss of **$99.8 million** for the six months ended May 31, 2025, and an accumulated deficit of **$838.6 million**, expecting continued losses for several years[216](index=216&type=chunk) - Substantial additional funding is required to advance clinical trials, expand the DEL-AI platform, and support potential commercialization, with failure to raise capital risking program delays or termination[222](index=222&type=chunk) [Risks Related to the Discovery and Development of Our Drug Candidates](index=48&type=section&id=Risks%20Related%20to%20the%20Discovery%20and%20Development%20of%20Our%20Drug%20Candidates) - The company's lead drug candidates are in early-stage clinical development, a phase with a high risk of failure[231](index=231&type=chunk) - The targeted protein degradation platform is a novel and unproven approach, making development time, cost, and success likelihood difficult to predict[235](index=235&type=chunk) - The company faces substantial competition from major pharmaceutical and biotech companies possessing greater financial resources and expertise in R&D, manufacturing, and commercialization[261](index=261&type=chunk)[263](index=263&type=chunk) [Risks Related to Dependence on Third Parties](index=55&type=section&id=Risks%20Related%20to%20Dependence%20on%20Third%20Parties) - The company depends on collaborations with Gilead, Sanofi, and Pfizer for R&D of certain drug candidates, with program success reliant on collaborators' performance and strategic decisions[269](index=269&type=chunk)[271](index=271&type=chunk) - Nurix relies on third-party CROs for clinical trials and CMOs for drug candidate supply, increasing risks related to quality, cost, and timeliness[276](index=276&type=chunk)[279](index=279&type=chunk) [Risks Related to Regulatory Approval and Marketing of Our Drug Candidates](index=73&type=section&id=Risks%20Related%20to%20Regulatory%20Approval%20and%20Marketing%20of%20Our%20Drug%20Candidates) - The regulatory approval process is lengthy, costly, and unpredictable, with no guarantee that any drug candidates will obtain marketing approval[346](index=346&type=chunk) - Approved products are subject to ongoing regulation, post-marketing restrictions, and potential market withdrawal if safety or efficacy issues emerge[366](index=366&type=chunk)[370](index=370&type=chunk) - Healthcare legislation, including the Inflation Reduction Act (IRA), and foreign price controls could negatively impact drug pricing and reimbursement, affecting future profitability[404](index=404&type=chunk)[406](index=406&type=chunk)[410](index=410&type=chunk) [Risks Related to Our Common Stock](index=98&type=section&id=Risks%20Related%20to%20Our%20Common%20Stock) - The company's stock price may be highly volatile due to factors like clinical trial results, regulatory developments, and market conditions[463](index=463&type=chunk) - Future sales of common stock to raise capital, including through the existing "at the market" facility, will dilute existing stockholders' ownership[467](index=467&type=chunk)[470](index=470&type=chunk) - Anti-takeover provisions in the company's charter and Delaware law could hinder beneficial acquisitions and prevent stockholders from replacing management[474](index=474&type=chunk)[475](index=475&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=105&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - There were no unregistered sales of equity securities[490](index=490&type=chunk) [Other Information](index=105&type=section&id=Item%205.%20Other%20Information) No director or Section 16 officer adopted or terminated a Rule 10b5-1 trading arrangement during the quarter - No director or Section 16 officer adopted or terminated a Rule 10b5-1 trading arrangement in the quarter[494](index=494&type=chunk) [Exhibits](index=106&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including an amendment to a sublease agreement, officer certifications, and XBRL data files

[Report Highlights](index=1&type=section&id=Report%20Highlights) Nurix reported positive clinical data for its lead candidate bexobrutideg, secured a $15 million license fee from Sanofi for extending their STAT6 collaboration, and announced FDA clearance for a Gilead-partnered IND. The company remains well-capitalized, ending the second quarter of 2025 with $485.8 million in cash and marketable securities - Presented updated data for **bexobrutideg (NX-5948)** at EHA2025 and ICML-18, showing a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM)[1](index=1&type=chunk) - Secured a **$15 million license fee** from Sanofi for the extension of the STAT6 collaboration to target type 2 inflammatory diseases[1](index=1&type=chunk) - Announced FDA clearance of the Investigational New Drug (IND) application for the novel IRAK4 degrader GS-6791/NX-0479, enabling partner Gilead to start a Phase 1 trial[1](index=1&type=chunk) - The company is well capitalized with cash and marketable securities of **$485.8 million** as of May 31, 2025[1](index=1&type=chunk)[14](index=14&type=chunk) [Recent Business Highlights](index=1&type=section&id=Recent%20Business%20Highlights) During the quarter, Nurix presented strong clinical data for bexobrutideg at major hematology conferences, leading to an Orphan Drug Designation from the EMA. The company advanced its strategic collaborations, receiving a $15 million payment from Sanofi for a license extension and achieving FDA IND clearance for a Gilead-partnered program. Additionally, Nurix showcased promising preclinical data for its broader pipeline and its AI-driven discovery platform at the AACR Annual Meeting - At EHA2025 and ICML-18, updated Phase 1 data for **bexobrutideg (NX-5948)** showed a robust objective response rate (ORR) of **80.9%** in r/r CLL patients, with a favorable safety profile and no dose-limiting toxicities[4](index=4&type=chunk) - Sanofi extended its license for Nurix's STAT6 program, triggering a **$15 million payment**. Nurix has received a total of **$127 million** under this collaboration and is eligible for an additional **$465 million** in milestones plus royalties[4](index=4&type=chunk) - In April 2025, the FDA cleared the IND for GS-6791/NX-0479, a first-in-class oral IRAK4 degrader developed in collaboration with Gilead for inflammatory diseases[4](index=4&type=chunk) - The European Medicines Agency (EMA) granted Orphan Drug Designation (ODD) to bexobrutideg for treating lymphoplasmacytic lymphoma, providing **10 years of market exclusivity** in the EU upon approval[6](index=6&type=chunk) - Presented preclinical data at AACR for its portfolio of brain-penetrant degraders and highlighted its DEL-AI platform, which uses a proprietary model to accelerate drug discovery[4](index=4&type=chunk)[5](index=5&type=chunk)[6](index=6&type=chunk) [Upcoming Program Highlights](index=2&type=section&id=Upcoming%20Program%20Highlights) Nurix is on track to initiate pivotal trials for bexobrutideg in CLL in the second half of 2025 and is expanding its development into autoimmune diseases. Clinical updates for its other pipeline candidates, zelebrudomide (NX-2127) and NX-1607, are also anticipated in the second half of 2025. The company expects to continue achieving milestones across its collaborations with Gilead, Sanofi, and Pfizer - **Bexobrutideg (NX-5948):** On track to initiate pivotal trials in CLL in H2 2025. Also exploring development in autoimmune diseases, with plans for a non-malignant hematology IND in 2025[7](index=7&type=chunk) - **Zelebrudomide (NX-2127):** Currently enrolling a dose escalation study with a new drug product. Future clinical updates are expected in H2 2025[8](index=8&type=chunk) - **NX-1607:** Ongoing Phase 1 trial in adults with various oncology indications. Clinical updates are anticipated in H2 2025[9](index=9&type=chunk) - **Strategic Collaborations:** Expects to achieve substantial research collaboration milestones with partners Gilead, Sanofi, and Pfizer[10](index=10&type=chunk) [Fiscal Second Quarter 2025 Financial Results](index=2&type=section&id=Fiscal%20Second%20Quarter%202025%20Financial%20Results) For the second quarter ended May 31, 2025, revenue surged to $44.1 million, a significant increase from $12.1 million in the prior-year period, primarily due to license and milestone payments from Sanofi and Gilead. R&D expenses increased to $78.1 million as the company accelerated clinical trial enrollment. Despite higher expenses, the net loss narrowed to $43.5 million, or ($0.52) per share, from $44.5 million, or ($0.71) per share, year-over-year. The company maintained a strong cash position of $485.8 million Financial Performance Summary | Financial Metric | Q2 2025 (ended May 31) | Q2 2024 (ended May 31) | Change | | :--- | :--- | :--- | :--- | | **Total Revenue** | $44.1 million | $12.1 million | +264% | | **R&D Expenses** | $78.1 million | $48.9 million | +60% | | **G&A Expenses** | $14.3 million | $11.7 million | +22% | | **Net Loss** | $43.5 million | $44.5 million | -2% | | **Net Loss Per Share** | ($0.52) | ($0.71) | Improved | - The increase in revenue was primarily driven by **$30 million** in license revenue from Sanofi and a **$5 million** clinical milestone from Gilead[11](index=11&type=chunk) - The rise in R&D expenses was mainly due to increased clinical, manufacturing, and consulting costs associated with accelerating the bexobrutideg trial and preparing for pivotal studies[12](index=12&type=chunk) - As of May 31, 2025, cash, cash equivalents, and marketable securities totaled **$485.8 million**. This figure does not include a **$4.0 million** milestone and a **$15.0 million** license payment received after the quarter's end[14](index=14&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section provides the unaudited condensed statements of operations for the three and six months ended May 31, 2025, and the condensed balance sheets as of May 31, 2025, compared to November 30, 2024 [Condensed Statements of Operations](index=5&type=section&id=Condensed%20Statements%20of%20Operations) For the three months ended May 31, 2025, Nurix reported total revenues of $44.1 million and a net loss of $43.5 million, or ($0.52) per share. This compares to revenues of $12.1 million and a net loss of $44.5 million, or ($0.71) per share, for the same period in 2024. For the six-month period, the net loss was $99.8 million in 2025 versus $86.1 million in 2024 | (in thousands, except per share data) | Three Months Ended May 31, 2025 | Three Months Ended May 31, 2024 | | :--- | :--- | :--- | | **Total revenue** | $44,056 | $12,092 | | **Total operating expenses** | $92,378 | $60,632 | | *Research and development* | *$78,096* | *$48,922* | | *General and administrative* | *$14,282* | *$11,710* | | **Loss from operations** | ($48,322) | ($48,540) | | **Net loss** | ($43,464) | ($44,546) | | **Net loss per share, basic and diluted** | ($0.52) | ($0.71) | [Condensed Balance Sheets](index=6&type=section&id=Condensed%20Balance%20Sheets) As of May 31, 2025, Nurix had total assets of $591.6 million, including $485.8 million in cash, cash equivalents, and marketable securities. Total liabilities were $144.0 million, and total stockholders' equity stood at $447.6 million. This reflects a decrease in total assets and equity from November 30, 2024, primarily due to cash used in operations | (in thousands) | May 31, 2025 | November 30, 2024 | | :--- | :--- | :--- | | **Cash, cash equivalents & marketable securities** | $485,781 | $609,583 | | **Total current assets** | $515,330 | $619,387 | | **Total assets** | $591,555 | $669,343 | | **Total current liabilities** | $75,614 | $95,854 | | **Total liabilities** | $143,952 | $142,350 | | **Total stockholders' equity** | $447,603 | $526,993 | [About Nurix Therapeutics, Inc.](index=3&type=section&id=About%20Nurix%20Therapeutics%2C%20Inc.) Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation medicines for cancer and inflammatory diseases. The company's pipeline includes wholly-owned clinical-stage assets (BTK degraders, CBL-B inhibitors) and preclinical programs, alongside partnered drug discovery collaborations with Gilead, Sanofi, and Pfizer. Nurix utilizes a fully AI-integrated discovery engine to advance its science - Focuses on the discovery, development, and commercialization of targeted protein degradation medicines for cancer and inflammatory diseases[15](index=15&type=chunk) - Wholly owned clinical pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B)[15](index=15&type=chunk) - Maintains strategic collaboration agreements with Gilead Sciences, Sanofi, and Pfizer for preclinical stage degraders of IRAK4, STAT6, and other programs[15](index=15&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section serves as a legal disclaimer, cautioning that the press release contains forward-looking statements regarding Nurix's future performance, plans, and the potential of its drug candidates. It highlights that these statements are subject to significant risks and uncertainties, and actual results could differ materially. Readers are advised to consult the 'Risk Factors' section in the company's SEC filings for a comprehensive understanding of these risks - The press release contains forward-looking statements concerning future plans, prospects, strategies, and the potential of its drug candidates[16](index=16&type=chunk) - These statements are not guarantees of future performance and are subject to risks and uncertainties, including the ability to advance drug candidates, timing of clinical trials, and funding[16](index=16&type=chunk) - Readers are cautioned not to place undue reliance on these statements and are referred to the "Risk Factors" section of Nurix's Quarterly Report on Form 10-Q for more details[16](index=16&type=chunk)

Core Insights - Nurix Therapeutics reported significant advancements in its clinical programs, including the presentation of updated data for bexobrutideg and the extension of collaborations with Sanofi and Gilead [1][2][3] Clinical Developments - Updated Phase 1 clinical data for bexobrutideg (NX-5948) showed an objective response rate (ORR) of 80.9% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with durable responses and a favorable safety profile [3][4] - The FDA cleared the IND application for GS-6791/NX-0479, a novel IRAK4 degrader, allowing Gilead to initiate Phase 1 trials [1][3] - The European Medicines Agency granted Orphan Drug Designation to bexobrutideg for lymphoplasmacytic lymphoma, providing incentives for its development [5] Financial Performance - Revenue for the fiscal quarter ended May 31, 2025, was $44.1 million, a significant increase from $12.1 million in the same quarter of 2024, primarily due to a $30 million license revenue from bexobrutideg [6][9] - Research and development expenses rose to $78.1 million from $48.9 million year-over-year, reflecting increased clinical and manufacturing costs [8][9] - The net loss for the quarter was $43.5 million, or $0.52 per share, compared to a net loss of $44.5 million, or $0.71 per share, in the prior year [9][10] Strategic Collaborations - Sanofi extended its license for Nurix's STAT6 program, resulting in a $15 million payment, with potential for an additional $465 million in future milestones [3][6] - Nurix continues to advance its collaborations with Gilead and Pfizer, expecting to achieve further research milestones [6][7] Cash Position - As of May 31, 2025, Nurix had cash and marketable securities totaling $485.8 million, down from $609.6 million as of November 30, 2024 [10][15]

Bexobrutideg Clinical Trial Updates - Bexobrutideg demonstrates rapid and durable clinical responses in relapsed/refractory CLL, with updated findings from an ongoing Phase 1a study presented at EHA 2025[5,9] - Bexobrutideg shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia (WM)[5,9] - In CLL patients, the objective response rate (ORR) was 80.9% (95% CI: 66.7–90.9), with 1 (2.1%) complete response (CR) and 37 (78.7%) partial responses (PR)[24] - In WM patients, the objective response rate (ORR) was 84.2%, with 2 (10.5%) very good partial responses (VGPR) and 11 (57.9%) partial responses (PR)[47] Bexobrutideg Safety and Tolerability - Bexobrutideg is well-tolerated in patients with relapsed/refractory CLL, with purpura/contusion (45.8%), diarrhea (31.3%), and fatigue (31.3%) being the most common treatment-emergent adverse events (TEAEs)[22] - In WM patients, the most common TEAEs were petechiae (27.3%), diarrhea (22.7%), and purpura/contusion (18.2%), with a favorable safety profile and no new safety signals[45] Bexobrutideg Mechanism and Market Potential - Bexobrutideg is a novel small molecule BTK degrader that can overcome treatment-emergent BTKi resistance mutations and disrupt BTK scaffolding[15,54] - The total BTKi sales were $10.6 billion in 2024 and projected worldwide sales for BTK-targeting agents in CLL are expected to exceed $15 billion by 2028[75] - Nurix is advancing bexobrutideg in CLL with a first pivotal study to be initiated in 2025, positioned to lead a new class of therapeutics in CLL[66] Regulatory Designations - Bexobrutideg has received U S Fast Track Designation from the FDA for CLL (January 2024) and WM (December 2024)[62,61] - Bexobrutideg has received EU PRIME designation from EMA in November 2024[62]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Nurix Therapeutics, Inc. (NRIX) due to higher revenues, with a focus on how actual results will compare to estimates [1][3]. Earnings Expectations - The consensus estimate predicts a quarterly loss of $0.70 per share, reflecting a year-over-year change of +1.4% [3][19]. - Expected revenues are $19.81 million, which represents a significant increase of 63.9% from the same quarter last year [3][19]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4][19]. - The Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.74%, suggesting a bullish outlook from analysts [12][19]. Earnings Surprise Potential - A positive Earnings ESP reading indicates a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [10][12]. - Nurix Therapeutics has a Zacks Rank of 2, enhancing the probability of surpassing the consensus EPS estimate [12][20]. Historical Performance - In the last reported quarter, Nurix Therapeutics was expected to post a loss of $0.72 per share but actually reported a loss of -$0.67, resulting in a surprise of +6.94% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14].

Core Viewpoint - Nurix Therapeutics, Inc. (NRIX) has seen a 2.3% increase in share price over the past four weeks, closing at $12.44, with analysts suggesting a potential upside of 143.4% based on a mean price target of $30.28 [1] Price Targets - The average of 18 short-term price targets ranges from a low of $16.00 to a high of $41.00, with a standard deviation of $6.49, indicating variability among estimates [2] - The lowest estimate suggests a 28.6% increase from the current price, while the highest estimate indicates a 229.6% upside [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about NRIX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.7%, with two estimates moving higher and no negative revisions [12] Zacks Rank - NRIX currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Nurix Therapeutics (NRIX) Update / Briefing June 12, 2025 08:00 AM ET Speaker0 Welcome to the New York's Therapeutics twenty twenty five investor call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. I would now like to turn the conference over to Newark's President and CEO, Arthur Sands. Arthur, you may begin. Speaker1 Thanks, Paul. Welcome to our call and our presentation today entitled meeting the needs of patients with CLL and Waldenstrom's ...

Core Viewpoint - Nurix Therapeutics is set to present new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) at the European Hematology Association Congress, highlighting the company's focus on targeted protein degradation medicines for cancer treatment [1][5]. Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [5]. - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on innovative drug design [5]. - Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline, supported by a fully AI-integrated discovery engine [5]. Clinical Trial Information - Bexobrutideg (NX-5948) is an investigational, orally bioavailable small molecule degrader of BTK, currently evaluated in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies [4]. - The ongoing clinical trial can be accessed for additional information at clinicaltrials.gov (NCT05131022) [4]. Upcoming Presentations - The company will host a webcast conference call on June 12, 2025, to discuss the new data from the Phase 1 clinical trial, which will be presented at the EHA2025 [1][2]. - Presentations at EHA2025 include findings on the clinical activity and safety of bexobrutideg in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia, scheduled for June 13 and June 14, respectively [6].

Nurix Therapeutics (NRIX) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Rutideg, which we call bexdeg for short, being a degrader. We've got an important new suffix on there to indicate it's a degrader. So, I'll be calling it bexdeg n x five nine four eight. Speaker1 Okay. Bexdeg. Speaker0 Yeah, bexdeg. Speaker1 Yeah, awesome. So, maybe just to clarify, this EHA update will be focused on the phase 1a, more mature data, but not from the phase 1b expansion cohort for CLL. Speaker0 Right. It'll be on the ...